We have located links that may give you full text access.
ENGLISH ABSTRACT
IN VITRO
JOURNAL ARTICLE
[Evaluation of a new and rapid antibiotic sensitivity method testing for Enterobacteriaceae responsible for urinary infections].
Pathologie-biologie 1997 May
URIFAST Es et Es Plus (International Microbio, Signes, France) are rapid antimicrobial susceptibility testing method in broth medium without using an automatic reader. A screening assay (URIFAST Quatro 1C ou URIFAST Twin 1C) is performed with a 4 or 9 antimicrobial agents with a concentration c' below the low critical concentration (c) defined by the Comité de l'Antibiogramme de la Société Française de Microbiologie (CA-SFM). When a bacterial strain is presumed resistant, an antimicrobial susceptibility test with the two critical concentrations (CA-SFM) can be performed with 5 or 10 antimicrobial agents antibiotiques (URIFAST Twin ABG ou URIFAST ABG). 140 strains of Enterobacteriaceae from urinary tract infections; E. coli (n = 94), P. mirabilis (n = 13), K. pneumoniae (n = 4), K. oxytoca (n = 6), C. diversus (n = 3), P. vulgaris (n = 1), M. morganii (n = 3), C. freundii (n = 4), E. aerogenes (n = 2), E. cloacae (n = 5) and S. marcescens (n = 5); were isolated with CPS ID2 (bioMérieux, Marcy l'Etoile, France). URIFAST results were compared to Rapid ATB Ur et ATB Ur results obtained after reading with ATB expression (bioMerieux). For each discrepancy, the minimal inhibitory concentration (MIC) by agar dilution was used as the reference method. Agreement obtained were 98.57% with Quatro 1C, 98.40% with Twin 1C, 98.14% with Twin ABG and 98.39% with ABG. 94% of beta-lactams susceptible Enterobacteriaceae were detected by the screening tray with the antimicrobial agent concentration c'. URIFAST Es et Es Plus are standardized and easy-to-use methods. Because of their good performances, the URIFAST methods can be used to test antimicrobial susceptibility for Enterobacteriaceae from urinary tract infections.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app